# Paxlovid in the Treatment of COVID-19 Patients With Uremia

> **NCT05386433** · EARLY_PHASE1 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19
- Uremia

## Interventions

- **DRUG:** Paxlovid
- **DRUG:** standard-of-care

## Key facts

- **NCT ID:** NCT05386433
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2022-07
- **Final completion:** 2022-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386433, "Paxlovid in the Treatment of COVID-19 Patients With Uremia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05386433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*